Our Delivery System

Introducing the Orbit SDS

Enabling microinjection into the subretinal space without a vitrectomy or retinotomy

Specifically designed and optimized for precise dose delivery

Our Focus


Controlled infusate delivery to the subretinal space.

Volume: This procedure enables delivery of a precise infusate dosage to the subretinal space and eliminates efflux into the vitreous.

Location: The Orbit SDS delivers the dose in close proximity to the target subretinal location.


Reproducible procedure delivering intentional results.

The Orbit SDS was designed to reduce intraoperative variabilities and provide for a standardized subretinal delivery procedure.


Avoids potential vitrectomy-related complications.

This procedure allows the surgeon to directly enter the subretinal space and does not require removal of the healthy vitreous. 


Please refer to the Instructions for Use for a detailed review of procedure steps and associated procedure risks associated with the Orbit Subretinal Delivery System.

Chang S. LXII Edward Jackson lecture: open angle glaucoma after vitrectomy. Am J Ophthalmol. 2006;141(6):1033-1043.

Hindawi Journal of Ophthalmology Volume 2020, Article ID 5085180, Incidence and Risk Factors of Iatrogenic Retinal Breaks 20-Gauge versus 25-Gauge Vitrectomy for Idiopathic Macular Hole Repair.

Contact Us

We'd love to hear from you. If you have an inquiry about our company, our investigational gene therapies, delivery systems or clinical trials, please contact us.

Follow Us

We are discovering and developing innovative medicines to preserve people’s sight and fight the devastating impact of blindness around the world. Our ultimate goal for our patients is – Vision For Life.

Orbit, Orbit SDS and the Orbit logos are trademarks of Gyroscope Therapeutics Limited.
© Gyroscope Therapeutics Limited, 2023.
All rights reserved

We are a global organization with teams based in:

  • London – UK
  • Philadelphia, San Francisco – USA